Work

Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.7518

Authors: Karen L. Reckamp, Marianna Koczywas, Mihaela C. Cristea, Jonathan Dowell, Brian Gardner, Ginger L Milne, Robert A. Figlin, Robert M. Elashoff, Steven M. Dubinett

Institutions: City Of Hope National Medical Center, City of Hope, The University of Texas Southwestern Medical Center, University of California, Los Angeles, Vanderbilt University, Cedars-Sinai Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2966644526

Cites:

Cited by: 3

Related to: 10